Immuneering (IMRX) stock drops 21% after phase 2a pancreatic cancer results for atebimetinib
https://seekingalpha.com/news/4537510-immuneering-plummets-following-phase-2-data-atebimetinib-pancreatic-cancer
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.